CPT · Q1 2026 Earnings

Narrative arc: Q2 Defensive substitution → Q3 Capitulating on rate, leaning on buyback → Q4 Unprecedented duration, mean-reversion conviction → Q1 Refusing to extrapolate, betting on April.

The framing of the growth problem has been reduced to a single variable: supply. Through 2025 management spoke about a complex mix of competitor rate-cutting, consumer sentiment, and absorption timing. This quarter Alex said flatly, "This is entirely a supply story. Demand in our markets are incredibly strong." That's a tighter, more confident thesis than Q4's "unprecedented duration" framing, but it's also more falsifiable — if the supply completions cadence (200K in 2025, dropping to 140–150K in 2026, then 135K in 2027, 120K in 2028) doesn't translate to pricing power in H2 2026, the supply explanation runs out of road.

Q1's bad-debt beat was explicitly walled off from full-year guidance — a discipline that's the inverse of Q3 2025's playbook. Last September Camden raised the FY Core FFO midpoint by $0.04 on a $0.01 Q3 beat funded by similar non-rate substitutions. This quarter, on a $0.04 Q1 Core FFO beat at the midpoint, management said: "we believe it is premature to extrapolate one quarter's performance into a full year trend particularly given market variability. As a result, we are reaffirming the midpoint of our full-year same-store revenue guidance at 0.75%." That's a deliberate posture change — refusing to convert a beat into a raise the way they did six months ago. The conservatism reads as either intellectual honesty about Q1's nature or implicit acknowledgment that H2 carries enough downside risk to absorb the upside.

Capital allocation framing has flipped acquisitions ahead of development for the first time in years. Q4 leaned into a $600M buyback authorization while deferring development; this quarter Alex extended the logic to direct property purchases: "Three years ago, developments, absolutely better than acquisitions. Today, what we're seeing is that you can buy real estate at a discount to replacement cost almost everywhere." The "we are the prettiest buyer in the market" line signals confidence on pipeline access, but the colloquialism — and the fact that Camden is articulating its capital availability as a marketing point — suggests the company expects to be deploying capital opportunistically rather than systematically through 2026.

Houston is no longer a fundamentals story — it's a sentiment story. Through 2025 Houston was framed as a quietly-decelerating but still-healthy market on the back of energy and migration. This quarter Alex named the problem: "if you look at all of the fundamentals in Houston, they are fantastic. When you actually look at the results though, they're not as great...Houston's consumer sentiment has fallen pretty dramatically in 26 as compared to 25." For a portfolio increasingly tilted toward Texas via the California 1031 redeployment, a sentiment-driven softness with no fundamental anchor is harder to underwrite than a supply problem with a known completion curve.

Baker (Denver CBD) was deferred with notably defensive language. The phrase "We are committing to doing what is right for our shareholders and making sure that we use our capital to create the best investments" was used to justify pulling back from a Denver development. For a REIT whose Q4 brief flagged Denver as a 2026 revenue-declining market on utility rebilling regulation, the defensive tone confirms that the development-deferral posture isn't tactical patience — it's specific market caution.